Sorry!! The article you are trying to read is not available now.
Merck Upgraded to “Outperform” at BMO (MRK)

On Monday analysts at BMO Financial upgraded pharmaceutical company Merck & Co., Inc. (MRK) after positive data from two early stage products.

The analysts boosted its rating on Merck from “Market Perform” to “Outperform” with a price target of $50. The target is a +13.5% increase from Friday’s closing price o $44.05.

Merck shares were up 47 cents, or +1.07%, in premarket trading on Monday.

The Bottom Line
Shares of Merck (MRK) have a 3.81% dividend yield, based on Friday’s closing stock price of $44.05. The stock has technical support in the $41-$42 price area. If the shares can firm up, we see overhead resistance around the $46-$48 price levels.

Merck & Co., Inc. (MRK) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here